Literature DB >> 3417290

The pulmonary biopsy in the early diagnosis of Wegener's (pathergic) granulomatosis: a study based on 35 open lung biopsies.

E J Mark1, O Matsubara, N S Tan-Liu, R Fienberg.   

Abstract

We reviewed open lung biopsies from 35 patients with Wegener's (pathergic) granulomatosis in order to study the histogenesis of the pulmonary lesions and to identify the early lesions. The process of pathergic necrosis is fundamental in the production of extravascular and vascular lesions and was divided into micronecrotic and macronecrotic types. Micronecrosis, usually with neutrophils (microabscesses), constitutes the early phase in the development of the pathognomonic organized palisading granuloma. The palisading granuloma differs from the compact granuloma of tuberculoid type, which occurs in infections and sarcoidosis but not in Wegener's (pathergic) granulomatosis. There is a progression of disease from micronecrosis to macronecrosis (widespread necrosis) and then to fibrosis. Macronecrosis surrounded by palisading histiocytes or diffuse granulomatous tissue indicates active disease, whereas necrosis surrounded by fibrous tissue indicates previously active disease. Most cases have a combination of micronecrosis, and fibrosis. We established the relative diagnostic value of various histologic features. Arteritis and phlebitis as classically described in Wegener's granulomatosis were present in most but not all cases. We believe that Wegener's granulomatosis primarily affects both vascular and extravascular collagen and reticulum and that vasculitis represents a primary necrosis of walls of blood vessels. We believe that the concept of Wegener's granulomatosis as a vasculitis is too restrictive and does not include many cases with only extravascular histologic changes.

Entities:  

Mesh:

Year:  1988        PMID: 3417290     DOI: 10.1016/s0046-8177(88)80088-1

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  20 in total

1.  Pulmonary Wegener's granulomatosis misdiagnosed as malignancy.

Authors:  S Uppal; N Saravanappa; J P Davis; C K Farmer; D J Goldsmith
Journal:  BMJ       Date:  2001-01-13

Review 2.  The Contribution of PTPN22 to Rheumatic Disease.

Authors:  Tomas Mustelin; Nunzio Bottini; Stephanie M Stanford
Journal:  Arthritis Rheumatol       Date:  2019-03-02       Impact factor: 10.995

Review 3.  Expression profiling in granulomatous lung disease.

Authors:  Edward S Chen; David R Moller
Journal:  Proc Am Thorac Soc       Date:  2007-01

Review 4.  Wegener's granulomatosis. Thoughts and observations of a pathologist.

Authors:  F Wegener
Journal:  Eur Arch Otorhinolaryngol       Date:  1990       Impact factor: 2.503

Review 5.  Pulmonary vasculitis: classification, clinical features, and management.

Authors:  A Ciaccia; M Ferrari; F M Facchini; G Caramori; L Fabbri
Journal:  Clin Rev Allergy Immunol       Date:  1997       Impact factor: 8.667

Review 6.  Interstital lung disease in ANCA vasculitis.

Authors:  Marco A Alba; Luis Felipe Flores-Suárez; Ashley G Henderson; Hong Xiao; Peiqi Hu; Patrick H Nachman; Ronald J Falk; J Charles Jennette
Journal:  Autoimmun Rev       Date:  2017-05-04       Impact factor: 9.754

Review 7.  Nomenclature and classification of vasculitis: lessons learned from granulomatosis with polyangiitis (Wegener's granulomatosis).

Authors:  J C Jennette
Journal:  Clin Exp Immunol       Date:  2011-05       Impact factor: 4.330

8.  Nasal biopsy in the early diagnosis of Wegener's (pathergic) granulomatosis. Significance of palisading granuloma and leukocytoclastic vasculitis.

Authors:  O Matsubara; N Yoshimura; Y Doi; A Tamura; E J Mark
Journal:  Virchows Arch       Date:  1996-04       Impact factor: 4.064

Review 9.  Mechanisms of endothelial cell injury in vasculitis.

Authors:  A A Pall; C O Savage
Journal:  Springer Semin Immunopathol       Date:  1994

Review 10.  Pathogenesis of antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis.

Authors:  J Charles Jennette; Ronald J Falk; Peiqi Hu; Hong Xiao
Journal:  Annu Rev Pathol       Date:  2013-01-24       Impact factor: 23.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.